Tabula Rasa HealthCare Inc (NASDAQ:TRHC) President Orsula V. Knowlton sold 8,000 shares of Tabula Rasa HealthCare stock in a transaction that occurred on Monday, September 17th. The shares were sold at an average price of $79.80, for a total transaction of $638,400.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
Shares of NASDAQ TRHC traded up $0.99 during trading on Friday, hitting $74.38. 428,631 shares of the company traded hands, compared to its average volume of 348,759. The company has a current ratio of 0.36, a quick ratio of 0.33 and a debt-to-equity ratio of 0.11. The firm has a market capitalization of $1.64 billion, a P/E ratio of -1,859.50, a P/E/G ratio of 6.13 and a beta of 2.85. Tabula Rasa HealthCare Inc has a fifty-two week low of $24.24 and a fifty-two week high of $91.16.
Tabula Rasa HealthCare (NASDAQ:TRHC) last posted its earnings results on Tuesday, August 7th. The company reported $0.20 EPS for the quarter, topping the consensus estimate of $0.08 by $0.12. The company had revenue of $48.60 million during the quarter, compared to the consensus estimate of $46.73 million. Tabula Rasa HealthCare had a negative net margin of 16.78% and a positive return on equity of 4.55%. Equities research analysts forecast that Tabula Rasa HealthCare Inc will post 0.53 EPS for the current year.
A number of research firms have weighed in on TRHC. Citigroup boosted their target price on shares of Tabula Rasa HealthCare to $100.00 and gave the stock a “buy” rating in a research note on Thursday. Robert W. Baird boosted their target price on shares of Tabula Rasa HealthCare from $70.00 to $90.00 and gave the company an “outperform” rating in a report on Wednesday, September 19th. BidaskClub lowered shares of Tabula Rasa HealthCare from a “strong-buy” rating to a “buy” rating in a report on Saturday, September 15th. Stifel Nicolaus initiated coverage on shares of Tabula Rasa HealthCare in a report on Tuesday, September 11th. They set a “hold” rating and a $95.00 price objective on the stock. Finally, Cantor Fitzgerald initiated coverage on shares of Tabula Rasa HealthCare in a report on Thursday, September 6th. They set an “overweight” rating and a $99.00 price objective on the stock. Three equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $71.75.
About Tabula Rasa HealthCare
Tabula Rasa HealthCare, Inc operates as a healthcare technology company in the United States. It offers medication risk management, pharmacy cost management, and medicare risk adjustment services. The company offers its technology-enabled products and services to prescribers, pharmacists, and healthcare organizations for medication risk management and risk adjustment.
Read More: Diversification
Receive News & Ratings for Tabula Rasa HealthCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa HealthCare and related companies with MarketBeat.com's FREE daily email newsletter.